An Open-Label, Randomized Phase III Study of Early Switch Maintenance Vs Delayed Second-Line Nivolumab in Advanced Stage Squamous Non-Small Cell Lung Cancer (NSCLC) Patients after Standard First-Line Platinum-Based Chemotherapy-Eden Trial GOIRC 04-2016.
LUNG CANCER(2025)
Key words
Squamous non-small cell lung cancer,Maintenance,Nivolumab,Immunotherapy,First-line,Randomized,Phase 3
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined